The nation of Zimbabwe has rejected a substantial American healthcare agreement valued at $367m (£272m) spanning five years over the United States' demand for confidential biological samples.
The decision became public following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesperson has since explained that the United States was seeking genetic material for scientific study and commercial gain while refused to share the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for continued dialogue to find a agreement agreeable to both sides so the country's vital HIV programme can proceed.
Broader Context
This development follows a comparable situation in neighbouring Kenya, where a court suspended a similar health funding agreement after legal challenges were filed about the safety of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and accountability.
According to reports, 16 nations in Africa have so far signed similar health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided significant advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population should a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting structures already established via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This mechanism is designed to ensure that when a country provides its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome continued discussions with our US partners on how future co-operation might be structured in a way that honours the independence and interests of each country."
Health Experts Reaction
Medical experts expressed it recognised the government's concerns, but suggested that talks must proceed considering a large portion of the nation's Aids initiatives were funded by international support.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," it said.
The halted deal underscores the complex debate between accepting crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.